Rationale for multiple risk intervention: The need to move from theory to practice

References

• No authors listedAfter the diagnosis: adherence and persistence with hypertension therapyAm J Manag Care200511S395S39916300455
   PubMed Web of Science ®Google Scholar
• AthyrosVGMikhailidisDPPapageorgiouAATargeting vascular risk in patients with metabolic syndrome but without diabetesMetabolism20055410657416092057
   PubMed Web of Science ®Google Scholar
• BacklundLBringJStrenderL-EHow accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients?Primary Health Care Research and Development2004514552
   Google Scholar
• Baena DiezJMAlvarezPBPinolFPAssociation between clustering of cardiovascular risk factors and the risk of cardiovascular diseaseRev Esp Salud Publica20027671511905401
   PubMedGoogle Scholar
• British Cardiac Society, [BCS], British Hypertension Society, Diabetes UKJBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practiceHeart200591Suppl 5v15216365341
   PubMedGoogle Scholar
• BrownMJMRC/BHF Heart Protection StudyLancet20023601782412480451
   PubMedGoogle Scholar
• BuchananTAXiangAHPetersRKPreservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic womenDiabetes200251279680312196473
   PubMed Web of Science ®Google Scholar
• Canadian Hypertension Society [CHS]CHEP Recommendations for the management of hypertension [online]2005 Accessed on April 10, 2007. URL: http://www.hypertension.ca/recommendations_2005/ultrashortexecsummary2005.pdf
   Google Scholar
• CheungBMOngKLManYBPrevalence of the metabolic syndrome in the United States national health and nutrition examination survey 1999 – 2002 according to different defining criteriaJ Clin Hypertens (Greenwich)200685627016896272
   PubMedGoogle Scholar
• ChiassonJLJosseRGGomisRAcarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trialJAMA20032904869412876091
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRSeventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension20034212065214656957
   PubMed Web of Science ®Google Scholar
• ConroyRMPyoralaKFitzgeraldAPEstimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE projectEur Heart J200324987100312788299
   PubMed Web of Science ®Google Scholar
• CsaszarAKekesEAbelTPrevalence of metabolic syndrome estimated by International Diabetes Federation criteria in a Hungarian populationBlood Press200615101616754273
   PubMed Web of Science ®Google Scholar
• DahlofBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet2002359995100311937178
   PubMed Web of Science ®Google Scholar
• DaskalopoulouSSMikhailidisDPElisafMPrevention and treatment of the metabolic syndromeAngiology20045558961215547646
   PubMed Web of Science ®Google Scholar
• De BackerGAmbrosioniEBorch-JohnsenKEuropean guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts)Eur J Cardiovasc Prev Rehabil200310S1S1014555889
   PubMed Web of Science ®Google Scholar
• DollRPetoRWheatleyKMortality in relation to smoking: 40 years’ observations on male British doctorsBMJ1994309901117755693
   PubMed Web of Science ®Google Scholar
• DREAM Trial InvestigatorsEffect of Ramipril on the incidence of diabetesN Engl J Med2006355 Sep 15 [Epub ahead of print].(b)
   Web of Science ®Google Scholar
• DREAM Trial InvestigatorsEffect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialLancet2006368109610516997664
   PubMed Web of Science ®Google Scholar
• ElabbassiWNHaddadHAThe epidemic of the metabolic syndromeSaudi Med J200526373515806201
   PubMed Web of Science ®Google Scholar
• El-AtatFMc/FarlaneSISowersJRDiabetes, hypertension and cardiovascular derangements: pathophysiology and managementCurr Hypertens Rep200662152315128475
   PubMed Web of Science ®Google Scholar
• EpsteinMDiabetes and hypertension: the bad companionsJ Hypertens200615S55S62
   Google Scholar
• ErhardtLRGottoAJrThe evolution of European guidelines: changing the management of cholesterol levelsAtherosclerosis2006185122016309687
   PubMed Web of Science ®Google Scholar
• ESH/ESC Guidelines CommitteeEuropean Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertensionJ Hypertens20032110115312777938
   PubMed Web of Science ®Google Scholar
• FordESGilesWHMokdadAHIncreasing prevalence of the metabolic syndrome among U.S. adultsDiabetes Care2004272444915451914
   PubMed Web of Science ®Google Scholar
• FordESPrevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the USDiabetes Care2005282745916249550
   PubMed Web of Science ®Google Scholar
• GilesTDBerkBCBlackHRExpanding the definition and classification of hypertensionJ Clin Hypertens (Greenwich)200575051216227769
   PubMedGoogle Scholar
• GoldmanDPJoyceGFKaraca-MandicPVarying pharmacy benefits with clinical status: the case of cholesterol-lowering therapyAm J Manag Care20061221816402885
   PubMed Web of Science ®Google Scholar
• GreenlandPKnollMDStamlerJMajor risk factors as antecedents of fatal and nonfatal coronary heart disease eventsJAMA2003290891712928465
   PubMed Web of Science ®Google Scholar
• GrundySMMetabolic syndrome: therapeutic considerationsHandb Exp Pharmacol20051701073316596797
   PubMedGoogle Scholar
• GrundySMMetabolic syndrome: connecting and reconciling cardiovascular and diabetes worldsJ Am Coll Cardiol200647109310016545636
   PubMed Web of Science ®Google Scholar
• GuDGuptaAMuntnerPPrevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the International Collaborative Study of Cardiovascular Disease in Asia (InterAsia)Circulation20051126586516043645
   PubMed Web of Science ®Google Scholar
• HackamDGAnandSSEmerging Risk Factors for Atherosclerotic Vascular Disease: A Critical Review of the EvidenceJAMA20032909324012928471
   PubMed Web of Science ®Google Scholar
• HansenDGGichangiAVachWEarly discontinuation: more frequent among general practitioners with high levels of prescribingEur J Clin Pharmacol200763861517618428
   PubMed Web of Science ®Google Scholar
• HansonRLImperatoreGBennettPHComponents of the “metabolic syndrome” and incidence of type 2 diabetesDiabetes2002513120712351457
   PubMed Web of Science ®Google Scholar
• HedleyAAOgdenCLJohnsonCLPrevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002JAMA200429128475015199035
   PubMed Web of Science ®Google Scholar
• HubertHBFeinleibMMcNamaraPMObesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart StudyCirculation198367968776219830
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation, [IDF]The IDF consensus worldwide definition of the metabolic syndrome2006 Accessed on April 10, 2007. URL: http://http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf
   Google Scholar
• JanssonJHBomanKMessnerTTrends in blood pressure, lipids, lipoproteins and glucose metabolism in the Northern Sweden MONICA project 1986–99Scand J Public Health Suppl200361435014660247
   PubMedGoogle Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436320223115207952
   PubMed Web of Science ®Google Scholar
• KitabchiAETemprosaMKnowlerWCRole of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metforminDiabetes20055424041416046308
   PubMed Web of Science ®Google Scholar
• KleinSLong-term pharmacotherapy for obesityObes Res200412Suppl163S166S15687412
   PubMedGoogle Scholar
• KnowlerWCBarrett-ConnorEFowlerSEReduction in the incidence of type 2 diabetes with lifestyle intervention or metforminN Engl J Med200234639340311832527
   PubMed Web of Science ®Google Scholar
• Koh-BanerjeePWangYHuFBChanges in body weight and body fat distribution as risk factors for clinical diabetes in US menAm J Epidemiol20041591150915191932
   PubMed Web of Science ®Google Scholar
• KshirsagarAVCarpenterMBangHBlood pressure usually considered normal is associated with an elevated risk of cardiovascular diseaseAm J Med20061191334116443415
   PubMed Web of Science ®Google Scholar
• LaaksonenDELakkaHMNiskanenLKMetabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort studyAm J Epidemiol20021561070712446265
   PubMed Web of Science ®Google Scholar
• LakkaHMLaaksonenDELakkaTAThe metabolic syndrome and total and cardiovascular disease mortality in middle-aged menJAMA200228827091612460094
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med200535214253515755765
   PubMed Web of Science ®Google Scholar
• LiZMaglioneMTuWMeta-analysis: pharmacologic treatment of obesityAnn Intern Med20051425324615809465
   PubMed Web of Science ®Google Scholar
• LindholmLHPerssonMAlaupovicPMetabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)J Hypertens20032115637412872052
   PubMed Web of Science ®Google Scholar
• LithellHHanssonLSkoogIThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens2003218758612714861
   PubMed Web of Science ®Google Scholar
• ManciaGTotal cardiovascular risk: a new treatment conceptJ Hypertens Suppl200624S17S2416601556
   PubMedGoogle Scholar
• McCallKLCraddockDEdwardsKEffect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysisPharmacotherapy200626129730616945052
   PubMed Web of Science ®Google Scholar
• McLaughlinTAbbasiFChealKUse of metabolic markers to identify overweight individuals who are insulin resistantAnn Intern Med2003139802914623617
   PubMed Web of Science ®Google Scholar
• McLaughlinTAllisonGAbbasiFPrevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individualsMetabolism200453495915045698
   PubMed Web of Science ®Google Scholar
• MoscaLLinfanteAHBenjaminEJNational study of physician awareness and adherence to cardiovascular disease prevention guidelinesCirculation200511149951015687140
   PubMed Web of Science ®Google Scholar
• NCEP Expert PanelThird Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation2002106314342112485966
   PubMed Web of Science ®Google Scholar
• NinomiyaJKL’ItalienGCriquiMHAssociation of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination SurveyCirculation200410942614676144
   PubMed Web of Science ®Google Scholar
• NissenSENichollsSJSipahiIEffect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trialJAMA200629515566516533939
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative GroupRandomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attackLancet200135810334111589932
   PubMed Web of Science ®Google Scholar
• SchrierRWEstacioROEslerAEffects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokesKidney Int20026110869711849464
   PubMed Web of Science ®Google Scholar
• SeverPSDahlofBPoulterNRPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet200336111495812686036
   PubMed Web of Science ®Google Scholar
• ShinitzkyHEKubJThe art of motivating behavior change: the use of motivational interviewing to promote healthPublic Health Nurs2001181788511359619
   PubMed Web of Science ®Google Scholar
• SowersJRRecommendations for special populations: diabetes melitus and the metabolic syndromeAm J Hypertens200616S41S45
   Google Scholar
• StamlerJVaccaroONeatonJDDiabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention TrialDiabetes Care199316434448432214
   PubMed Web of Science ®Google Scholar
• SukSHSaccoRLBoden-AlbalaBAbdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke StudyStroke200334715869212775882
   PubMed Web of Science ®Google Scholar
• ThomasFRudnichiABacriAMCardiovascular mortality in hypertensive men according to presence of associated risk factorsHypertension20013712566111358937
   PubMed Web of Science ®Google Scholar
• TolonenHKeilUFerrarioMEvansAPrevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA ProjectInt J Epidemiol2005341819215333620
   PubMed Web of Science ®Google Scholar
• TorgersonJSHauptmanJBoldrinMNXENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patientsDiabetes Care2004271556114693982
   PubMed Web of Science ®Google Scholar
• VitaleCMarazziGVolterraniMMetabolic syndromeMinerva Med2006972192916855517
   PubMedGoogle Scholar
• VolpeMTocciGIntegrated cardiovascular risk management for the future: lessons learned from the ASCOT trialAging Clin Exp Res200617465316640173
   PubMedGoogle Scholar
• WaghAStoneNJTreatment of metabolic syndromeExpert Rev Cardiovasc Ther200422132815151470
   PubMedGoogle Scholar
• WhitworthJA2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertensionJ Hypertens20032119839214597836
   PubMed Web of Science ®Google Scholar
• WildSHByrneCDByrneCDWildSHThe global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular diseaseThe Metabolic Syndrome2005ChichesterJohn Wiley & Sons Ltd143
   Google Scholar
• WilliamsBPoulterNRBrownMJGuidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IVJ Hum Hypertens2004181398514973512
   PubMed Web of Science ®Google Scholar
• WiviottSDde LemosJACannonCPA tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22Circulation200611314061416534008
   PubMed Web of Science ®Google Scholar
• World Health Organization, [WHO]The European Health Report2002 Accessed on April 10, 2007. URL: http://http://www.euro.who.int/europeanhealthreport
   Google Scholar
• YusufSHawkenSOunpuuSEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyLancet20043649375215364185
   PubMed Web of Science ®Google Scholar
• YusufSPfefferMASwedbergKEffects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialLancet20033627778113678871
   PubMed Web of Science ®Google Scholar
• YusufSSleightPPogueJEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med20003421455310639539
   PubMed Web of Science ®Google Scholar
• ZieveFJThe metabolic syndrome: diagnosis and treatmentClin Cornerstone20046Suppl 3S5S1315707265
   PubMedGoogle Scholar